NNC0114-0006
- Generic Name
- NNC0114-0006
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- L1SQ55DADE
- Background
NNC0114-0006 is an anti-interleukin 21 monoclonal antibody
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 308
- Registration Number
- NCT02443155
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 53
- Registration Number
- NCT01751152
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01689025
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Houston, Texas, United States
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT01647451
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01565408
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Yaroslavl, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath